Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Huitema, A.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(6)
+
-
Availability
Open access
(4)
+
-
Metadata Only
(2)
+
-
Creation Date
2015
(3)
+
-
Faculty
Faculty of Science
(5)
+
-
Leiden University Medical Center (LUMC)
(1)
+
-
Collection
Leiden Academic Centre for Drug Research (LACDR)
(3)
+
-
Leiden Institute of Chemistry (LIC)
(2)
+
-
Author
Huitema, A.
(6)
+
-
Bader, J.
(2)
+
-
Beijnen, J.
(2)
+
-
Berset, C.
(2)
+
-
Berthod, G.
(2)
+
-
Driessen, C.
(2)
+
-
Gupta, A.
(2)
+
-
Hasselt, J.G.C. van
(2)
+
-
Hawle, H.
(2)
+
-
Hess, D.
(2)
+
-
Hitz, F.
(2)
+
-
Hussein, Z.
(2)
+
-
Joerger, M.
(2)
+
-
Kraus, M.
(2)
+
-
Mey, U.J.
(2)
+
-
Overkleeft, H.S.
(2)
+
-
Pabst, T.
(2)
+
-
Rosing, H.
(2)
+
-
Schellens, J.
(2)
+
-
Sessa, C.
(2)
+
-
Xyrafas, A.
(2)
+
-
Show more
Language
en
(5)
+
-
Search results
(1 - 6 of 6)
show grid
show list
save search
Impact of bariatric surgery in the short and long term
Carboplatin-cyclophosphamide or paclitaxel without or with bevacizumab as first-line treatment for metastatic triple-negative breast cancer (BOOG 2013-01)
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin
Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin